News

Yahoo Finance3y
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases - Yahoo Finance
NEW YORK and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines ...
Business Wire6y
Beam Therapeutics Presents Data on Multiplex Base Editing for Engineered CAR-T Cells at American Society of Gene and Cell Therapy 22 - Business Wire
In the experiment, the base editor BE4 demonstrated high efficiency multiplex base editing of three cell surface targets in primary human T cells (TRAC, B2M, and PD-1), knocking out expression of ...
Business Wire5y
Beam Therapeutics Presents Preclinical Data for Complementary Base Editing Approaches for Hemoglobinopathies at ASH 2019 - Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data for the company’s ...